Why PBM Contracts That Look Good on Paper Can Cost You More in Reality
By: Kevin Kobielski, President of Navion At first glance, many pharmacy benefit proposals can feel impressive—thick with rebate guarantees, discount percentages, and […]
Precision Medicine in Practice: The Growing Value of Pharmacogenomic (PGx) Testing
By Beckie Fenrick, PharmD, MBA and Jason Peterson, RPh As pharmacy costs climb and personalization reshapes every corner of healthcare,
Transparent vs. Traditional PBMs: What’s the Best Choice?
By: Kevin Kobielski, President of Navion In the world of pharmacy benefits, “transparency” has become a golden word—implying clarity, fairness,
The Rise of Direct-to-Consumer Drug Pricing
Direct-to-consumer pharmacy programs aren’t new—but they’re about to get a lot bigger. Pharmaceutical manufacturers offer select medications directly to patients at flat or discounted
Navion Update: Pfizer Announces Most Favored Nation (MFN) Drug Pricing in the U.S.
On September 30, 2025, during a joint White House press conference, Pfizer announced a landmark pricing agreement to lower drug
Q3 2025 FDA Drug Approvals: Wegovy, HIV PrEP, RSV Protection & More
By Beckie Fenrick, PharmD, MBA and Jason Peterson, RPh The FDA’s Q3 2025 approvals mark a pivotal quarter, with new
Pharmacy Spend: Why Clinical Strategy Is the New Cost Strategy
By: Kevin Kobielski, President of Navion For years, the pharmacy benefits conversation has revolved around unit costs, rebates, and discounts.
